Ocular toxicity studies have unique features that require specific technical considerations and pathology reporting expectations. In this webinar, the featured speaker will discuss technical considerations including species selection, anatomic differences and necropsy and histology techniques. In addition, the speaker will discuss pathology reporting expectations such as basic report components, interpretation of findings, adversity determination and ophthalmic examination correlates.
After participating in the webinar, attendees should be able to:
- Describe the ocular anatomic differences between commonly used species and why this is an important consideration in ocular toxicity studies
- Explain the current recommendations for ocular sampling and sectioning
- Summarize the expected components of an ocular toxicity pathology report
Register to learn about the technical considerations and pathology reporting expectations in ocular toxicity studies.
Dr. Stephanie Shrader, DVM, PhD, DACVP, Director, General Toxicologic Pathology, StageBio
Dr. Stephanie Shrader joined the StageBio team as a Senior Pathologist in 2019. She has a strong background and primary subspecialty interest in ocular pathology with extensive experience evaluating a variety of ophthalmic drugs, animal models, ocular dosing routes and ocular medical devices. Prior to StageBio, Dr. Shrader spent two years at Charles River Laboratories in Spencerville, Ohio where she also served as the site’s IACUC chairperson. She is an active member of the American College of Veterinary Pathologists (ACVP) and the Society of Toxicologic Pathology (STP), enjoys collaborating with her colleagues to author book chapters and peer reviewed journal articles and serves as a peer reviewer for several journals. Dr. Shrader earned a BS in biological sciences from Wilson College in Pennsylvania, a DVM from the Virginia-Maryland College of Veterinary Medicine and completed her anatomic pathology residency and PhD in biomedical sciences at the Auburn University College of Veterinary Medicine.
Who Should Attend?
- Study Directors
What You Will Learn
Attendees will learn about:
- The ocular anatomic differences between commonly used species and why this is an important consideration in ocular toxicity studies
- The current recommendations for ocular sampling and sectioning
- The expected components of an ocular toxicity pathology report
StageBio is a leading provider of GLP-compliant necropsy, histology, pathology, and specimen archiving and biorepository services for the biopharmaceutical, medical device, academic, and contract research industries. The company operates four GLP laboratories as well as three GLP specimen archiving facilities in the U.S., along with one GLP laboratory in Europe. We will continue to make investments in facility and technology infrastructure to meet the growing demand for high-quality histopathology services globally. StageBio has a team of 30+ board-certified veterinary pathologists and more than 100 laboratory technicians on staff supporting our unified commitment to quality, scientific integrity, and client satisfaction. Learn more at stagebio.com.